Searchable abstracts of presentations at key conferences in endocrinology

ea00100we3.3 | Workshop E: Disorders of the gonads | SFEEU2024

Menopause related libido loss: is testosterone replacement always needed?

Iacuaniello Davide

Menopause may cause a constellation of symptoms associated with reduced quality of life. Loss of libido is a common one, although there still is uncertainty about its management in clinical practice. This 50-year-old lady was seen in the endocrine clinic complaining about fatigue and loss of libido. The patient’s journey started 3 years earlier when she was commenced on hormone replacement therapy (HRT) in the community. After a short treatment with Evorel Sequi, as libid...

ea0094p365 | Neuroendocrinology and Pituitary | SFEBES2023

Suboptimal treatment of acromegaly potentially leading to onset and progression of B cell lymphoma

Iacuaniello Davide , Majeed Waseem , Pathmanaban Omar , Roncaroli Federico , Kearney Tara

Acromegaly is a rare endocrine disorder mostly caused by a growth hormone (GH)-secreting pituitary adenoma. The aim of treatment is to normalize GH/IGF1 levels to limit disease burden. Growth hormone hypersecretion is associated with an increased cancer risk; cases of Acromegaly complicated by lymphoma have been reported. We share a clinical case characterized by suboptimal treatment, potentially leading to advancing orbital lymphoma. This 49-year-old man was diagnosed with Ac...

ea0049ep34 | Adrenal cortex (to include Cushing's) | ECE2017

The treatment with dual release hydrocortisone in patients with adrenal insufficiency: correlation between change of the evening cortisol exposure time profile and change in metabolic profile, depression status and quality of life

Simeoli Chiara , Ferrigno Rosario , Pivonello Claudia , Auriemma Renata Simona , Negri Mariarosaria , Di Gennaro Gilda , Iacuaniello Davide , De Martino Maria Cristina , Colao Annamaria , Pivonello Rosario

Conventional glucocorticoids (CGCs) are unable to mimic physiological cortisol rhythm in adrenal insufficiency (AI), resulting in increased metabolic morbidity and impaired quality of life (QoL). Non-physiological cortisol pattern and elevated evening cortisol levels may be responsible for the increased risk of metabolic disorders observed in AI patients under CGCs. Once daily dual-release-hydrocortisone (DR-HC), which better reproduces physiological daily cortisol profile, si...

ea0049ep927 | Pituitary - Basic | ECE2017

Ketoconazole induces inhibition of cell viability and apoptosis in an ACTH-secreting tumour cell line model

Patalano Roberta , Pivonello Claudia , Solari Domenico , Vitulli Francesca , Iacuaniello Davide , Leo Monica De , Negri Mariarosaria , Provvisiero Donatella Paola , Cavallo Luigi Maria , Cappabianca Paolo , Colpo Annamaria , Pivonello Rosario

Chronic cortisol excess as a consequence of ACTH overproduction from a pituitary tumour is responsible for the development of Cushing’s disease (CD). The first-line treatment for CD is pituitary surgery, but medical treatment is an alternative second-line approach to control cortisol excess. Among pharmacological agents, the adrenal-blocking drug ketoconazole (KT), is able to control cortisol excess in the majority of patients with CD. During KT treatment, the adrenal blo...

ea0049ep1056 | Pituitary - Clinical | ECE2017

Effects of pasireotide treatment on cardio-metabolic risk in patients with Cushing’s disease: an Italian, multicenter study

Albani Adriana , Ferrau Francesco , Messina Erika , Pivonello Rosario , Scaroni Carla , Giordano Carla , Cozzolino Alessia , Zilio Marialuisa , Guarnotta Valentina , Ciresi Alessandro , Iacuaniello Davide , Alibrandi Angela , Colao Annamaria , Cannavo Salvatore

: Patients with Cushing’s disease (CD) have increased cardiovascular risk due to metabolic alterations caused by glucocorticoids excess. Pasireotide, a multireceptor-targeted somatostatin analogue, is a therapeutic option in CD patients in whom surgery is not curative or not feasible. Pasireotide has been shown to be effective in controlling hypercortisolism and to improve metabolic features. Recently, the visceral adiposity index (VAI) has been proposed as a marker of vi...

ea0041gp17 | Adrenal (1) | ECE2016

Improved evening and nocturnal cortisol exposure time profile in patients with adrenal insufficiency treated with dual release hydrocortisone: correlation with improvement in metabolic profile

Simeoli Chiara , Ferrigno Rosario , De Martino Maria Cristina , Auriemma Renata Simona , Pivonello Claudia , Negri Mariarosaria , Iacuaniello Davide , Di Gennaro Gilda , Colao Annamaria , Pivonello Rosario

Conventional glucocorticoids (GCs) are unable to mimic physiological cortisol rhythm in adrenal insufficiency (AI), with a significant impact on morbidity and mortality. Possible explanations are supra-physiological doses and impaired cortisol profile. In particular, elevated evening cortisol levels were related to glucose tolerance and insulin sensitivity alterations and visceral obesity. Once-daily-dual-release-hydrocortisone (OD-DR-HC), better reproducing the physiological ...

ea0037ep48 | Adrenal cortex | ECE2015

The treatment with ‘dual release' hydrocortisone (DR-HC) in congenital adrenal hyperplasia: short-term (6 months) and long-term (12 months) follow-up after the switch from conventional glucocorticoids to DR-HC

Simeoli Chiara , De Martino Maria Cristina , Iacuaniello Davide , Mannarino Teresa , Cozzolino Alessia , De Leo Monica , Pivonello Claudia , Negri Mariarosaria , De Angelis Cristina , Colao Annamaria , Pivonello Rosario

In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, life-long glucocorticoid (GC) treatment is often required to replace cortisol deficiency and to avoid the ACTH-dependent androgen levels increase. However, in these patients, the multiple daily doses required with conventional GCs can cause cortisol overexposure, leading to an increased risk of metabolic syndrome (MS), an impaired quality of life (QoL), and poor treatment compliance (TC). T...

ea0035p29 | Adrenal cortex | ECE2014

The treatment with glucocorticoids in congenital adrenal hyperplasia: short- and long-term effects of the switch from conventional glucocorticoids to ‘dual release' hydrocortisone on metabolic and hormonal profile

Simeoli Chiara , Mannarino Teresa , De Martino Maria Cristina , Cozzolino Alessia , Iacuaniello Davide , De Leo Monica , Auriemma Renata S , Di Somma Carolina , Colao Annamaria , Pivonello Rosario

Life-long glucocorticoid (GC) treatment is needed in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency in order to replace cortisol deficiency and to control ACTH and consequently androgen levels. Therefore, patients with CAH tend to have an increased risk of metabolic syndrome (MS), probably due to cortisol overexposure, caused by multiple daily doses of conventional GCs, unable to mimic cortisol circadian rhythm. The current study aimed at i...

ea0032p21 | Adrenal cortex | ECE2013

Bilateral inferior petrosal sinus sampling in cushing's syndrome: comparison between an old and a new technique in naples experience

De Leo Monica , Tortora Fabio , Cozzolino Alessia , Simeoli Chiara , Iacuaniello Davide , Albano Aurora , Briganti Francesco , Cirillo Sossio , Colao Annamaria , Pivonello Rosario

Introduction: Bilateral inferior petrosal sinus sampling (BIPSS) is the test that offers the highest diagnostic accuracy in the differential diagnosis between pituitary and ectopic Cushng’s syndrome (CS). The aim of this study was to compare the diagnostic accuracy of BIPSS performed in the last six years, after the change in the technical procedure with that performed in the past period in Naples centre.Patients and methods: Seventeen patients with...

ea0032p917 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Effect of short- and long-term treatment with pasireotide on hemochrome in patients with Cushing's disease

Cozzolino Alessia , Simeoli Chiara , Trementino Laura , De Leo Monica , Vitale Pasquale , Iacuaniello Davide , Albano Aurora , Boscaro Marco , Colao Annamaria , Arnaldi Giorgio , Pivonello Rosario

Introduction: Generously supported by IPSEN)-->Glucocorticoids (GC) have a stimulatory effect on neutrophils and an inhibitory effect on the other leukocyte subpopulations. A potential stimulatory effect on erythropoiesis has been also hypothesized. The aim of our study was to evaluate the effect of pasireotide treatment on hemochrome parameters in patients with endogenous pituitary-dependent glucocorticoid excess or Cushing’s d...